Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research
May 30, 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Wistar Research Identifies Mechanisms for Selective Multiple Sclerosis Treatment Strategy
May 28, 2024 11:30 ET
|
The Wistar Institute
PHILADELPHIA, PA, May 28, 2024 (GLOBE NEWSWIRE) -- PHILADELPHIA — (May 28, 2024) — The Wistar Institute’s Paul M. Lieberman, Ph.D., and lab team led by senior staff scientist and first author,...
Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab
May 13, 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
NeurologyLive® and CMSC Announce the 3rd Annual Class of Inductees
May 01, 2024 09:00 ET
|
NeurologyLive
CRANBURY, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- NeurologyLive® and the Consortium of Multiple Sclerosis Centers (CMSC) are pleased to announce the 2024 Giants of Multiple Sclerosis® inductees. The...
Alumis Announces First Participant Dosed in Phase 1 Clinical Trial of CNS Penetrant Allosteric TYK2 Inhibitor A-005
April 30, 2024 08:00 ET
|
Alumis Inc
Alumis Inc. today announced that dosing has commenced in a Phase 1 clinical trial of A-005 in healthy participants.
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
April 26, 2024 09:23 ET
|
Tevogen Bio Inc
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
April 25, 2024 10:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Multiple Sclerosis Market To Reach USD 39.9 Billion By 2032, Report By DataHorizzon Research
April 25, 2024 08:50 ET
|
DataHorizzon Research
Fort Collins, Colorado, April 25, 2024 (GLOBE NEWSWIRE) -- Rise in cases of multiple sclerosis to trigger the need for vaccines and diagnosis. Multiple sclerosis (MS) is a condition characterized...
Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program
April 23, 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, April 23, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
April 22, 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
70% of Patients in the Expanded Access Program (EAP) Have Seen Measurable Clinical Improvement in Their Fatigue After Six Months of Follow-upAll Patients Have Either Stabilized or Improved on Nasal...